Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Herceptin Adjuvant (HERA) Trial Study Team. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.<em>Lancet</em> 2017; <bold>389</bold>: 1195-205. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/S0140-6736(16)32616-2" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S0140-6736(16)32616-2</a></pub-id>
Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. <em>Breast</em> 2013; 22: 152-5. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.breast.2013.07.029" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.breast.2013.07.029</a></pub-id>
Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <em>Eur Heart J</em> 2016; <bold>37</bold>: 2768-801. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1093/eurheartj/ehw211" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1093/eurheartj/ehw211</a></pub-id>
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. <em>N Engl J Med</em> 2005; <bold>353</bold>: 1659-72. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1056/NEJMoa052306" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa052306</a></pub-id>
Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. <em>Lancet Oncol</em> 2005; <bold>6</bold>: 557-65. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/S1470-2045(05)70251-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/S1470-2045(05)70251-5</a></pub-id>
Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. <em>Br J Cancer</em> 2013; <bold>108</bold>: 179-82. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1038/bjc.2012.575" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1038/bjc.2012.575</a></pub-id>
Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, Bangalore S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: a systematic review and meta-analysis. <em>Clin Cardiol</em> 2017; <bold>40</bold>: 73-81. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1002/clc.22631" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1002/clc.22631</a></pub-id>
Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, et al. [Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].[French]. <em>Cancer Radiother</em> 2013; <bold>17</bold>: 183-90. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/j.canrad.2012.12.006" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.canrad.2012.12.006</a></pub-id>
Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. <em>N Engl J Med</em> 2008; <bold>358</bold>: 2107-16. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1056/NEJMoa0707064" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJMoa0707064</a></pub-id>
Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of streching. <em>Endocrinology</em> 1993; <bold>132</bold>: 1961-70. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1210/endo.132.5.8477647" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1210/endo.132.5.8477647</a></pub-id>
Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. <em>Heart</em> 2003; <bold>89</bold>: 745-51.
Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. <em>Radiol Oncol</em> 2014; <bold>48</bold>: 105-12. <pub-id pub-id-type="doi"><a href="https://doi.org/10.2478/raon-2013-0040" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2478/raon-2013-0040</a></pub-id>
Marinko T. Impact of concurrent radiotherapy and treatment with trastuzumab on cardiotoxicity of breast cancer patients. [Dissertation]. Ljubljana: Faculty of Medicine, University of Ljubljana; 2014.
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013. [cited 2017 Nov 15]. Available at <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2017. [cited 2017 Nov 7]. Available at: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf">https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</ext-link>
Giannuzzi P, Temporelli PL, Bosimini E, Silva P, Imparato A, Corrà U, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. <em>J Am Coll Cardiol</em> 1996; <bold>28</bold>: 383-90. <pub-id pub-id-type="doi"><a href="https://doi.org/10.1016/0735-1097(96)00163-5" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/0735-1097(96)00163-5</a></pub-id>
Hall EJ, Giaccia AJ. <em>Radiobiology for the radiologist</em>. Chapter 20. 7th edition. Philadelphia: Lippincott Williams & Wilkins, Wolters Kluwer; 2012. p 343.